Jazz Pharmaceuticals plc (JAZZ) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Jazz Pharmaceuticals’s revenue went from $1.5B in fiscal 2016 to $4.3B in fiscal 2025, growth of about 12.4% a year.
Net income in fiscal 2025 was -$356M, a net margin of -8.3%; the best year in this period was 2024 with $560M.
Over the twelve months to September 30, 2026, revenue was $4.7B and net income $206M.
Free cash flow was $1.3B in fiscal 2025 and positive in 10 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7B | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B | $2.4B | $2.2B | $1.9B | $1.6B | $1.5B |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | $426M | -$430M | $717M | $579M | -$66M | $170M | $378M | $532M | $615M | $529M | $592M |
| Net income | $206M | -$356M | $560M | $415M | -$224M | -$330M | $239M | $523M | $447M | $488M | $397M |
| EPS (diluted) | $3.38 | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 |
| R&D | $829M | $783M | $884M | $850M | $590M | $506M | $335M | $300M | $227M | $198M | $162M |
| Revenue growth | — | +4.9% | +6.1% | +4.8% | +18.3% | +30.9% | +9.3% | +14.3% | +16.8% | +8.8% | +12.3% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.7B | $1.4B | $1.4B | $1.1B | $1.3B | $779M | $900M | $776M | $799M | $693M | $592M |
| Capital spending | -$71M | -$59M | -$38M | -$24M | -$29M | -$28M | -$15M | -$40M | -$20M | -$29M | -$10M |
| Free cash flow | $1.6B | $1.3B | $1.4B | $1.1B | $1.2B | $751M | $885M | $736M | $779M | $664M | $583M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Buybacks | $225M | $125M | $311M | $270M | $54000 | $0 | $147M | $301M | $524M | $99M | $278M |
| Stock-based pay | $296M | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.4B | $2.4B | $1.5B | $881M | $591M | $1.1B | $637M | $310M | $386M | $366M |
| Debt | — | $5.4B | $6.2B | $5.8B | $5.8B | $6.2B | $2.2B | $1.8B | $1.7B | $1.6B | $2.0B |
| Equity | — | $4.3B | $4.1B | $3.7B | $3.1B | $4.0B | $3.7B | $3.1B | $2.8B | $2.7B | $1.9B |
| Total assets | — | $11.7B | $12.0B | $11.4B | $10.8B | $12.3B | $6.5B | $5.5B | $5.2B | $5.1B | $4.8B |
| Shares (diluted) | 65M | 61M | 66M | 72M | 63M | 60M | 57M | 58M | 61M | 61M | 62M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 9.0% | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% | 16.0% | 24.6% | 32.5% | 32.7% | 39.8% |
| Net margin | 4.4% | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% |
| FCF margin | 34.4% | 30.4% | 33.4% | 27.9% | 34.0% | 24.3% | 37.4% | 34.1% | 41.2% | 41.0% | 39.2% |
| ROIC | — | -2.5% | 5.5% | 4.8% | -0.4% | 1.3% | 5.6% | 8.6% | 11.6% | 9.7% | 11.3% |
| ROE | — | -8.2% | 13.7% | 11.1% | -7.3% | -8.3% | 6.5% | 16.8% | 16.2% | 18.0% | 21.1% |
Frequently asked questions
What is Jazz Pharmaceuticals’s annual revenue?
$4.3B in fiscal 2025 and $4.7B over the twelve months to September 30, 2026.
How much profit does Jazz Pharmaceuticals make?
Net income was -$356M in fiscal 2025 (net margin -8.3%).
Is Jazz Pharmaceuticals’s revenue growing?
Yes: revenue rose 4.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.